Target intelligence / Profile preview

Tight junction protein (TJP) (TJP)

Target
TJP
Molecular classification
Cell adhesion molecule, Structural protein, Scaffolding protein, Transmembrane protein
01

Overview

Tight junction proteins are the fundamental components of the intestinal mucosal barrier, forming a regulated seal between adjacent epithelial cells to control paracellular permeability [StatPearls, 2023]. This complex consists of transmembrane proteins such as claudins, occludin, and junctional adhesion molecules (JAMs), which are linked to the intracellular actin cytoskeleton via scaffolding proteins like zonula occludens-1 (ZO-1) [Nature Reviews Gastroenterology & Hepatology, 2014]. Their primary biological function is to maintain a selective barrier that allows the absorption of nutrients and water while excluding pathogens, toxins, and environmental antigens from the systemic circulation. Dysfunction of these proteins leads to increased intestinal permeability, a condition often associated with inflammatory bowel disease (IBD), celiac disease, and various systemic autoimmune disorders [Frontiers in Immunology, 2021]. Pharmacological targeting of tight junctions involves either the use of stabilizers to restore barrier integrity, such as the zonulin antagonist larazotide acetate, or the use of modulators to facilitate the oral delivery of large therapeutic molecules [Pharmaceutics, 2021]. Given their ubiquitous presence in epithelial tissues, therapeutic strategies must carefully balance local efficacy in the gut with the risk of systemic barrier disruption.

Other names
Zonula occludensOccludinClaudinJunctional adhesion moleculeJAMIntestinal barrier proteinsApical junctional complex
02

Mechanism of action

Regulation of paracellular permeability through the modulation of tight junction assembly, disassembly, and protein expression levels [PubMed, 2022].

03

Biological functions

Cell-cell adhesionParacellular transport regulationCell polarityBarrier functionSignal transduction
04

Disease associations

Inflammatory bowel diseaseCeliac diseaseIrritable bowel syndromeType 1 diabetesMultiple sclerosisInfectionInflammation
05

Safety considerations

Risk of systemic exposure to luminal pathogensPotential for malabsorptionOff-target barrier disruption in other tissues (e.g., blood-brain barrier)
06

Interacting drugs

Larazotide acetate

5 more in the full profile.

07

Biomarkers

ZonulinClaudin-3Lipopolysaccharide (LPS)LPS-binding protein (LBP)Fatty acid-binding protein 2 (FABP2)Lactulose-mannitol ratio

Beyond the preview

Go deeper on Tight junction protein (TJP) (TJP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tight junction protein (TJP) (TJP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call